7 Blue-Chip Stocks to Buy for Safety in This Volatile Market

In This Article:

I’m on the hunt for blue-chip stocks to buy for safety in this volatile market. The problem is the definition of what makes a company blue chip varies. Some believe it’s consistent and increasing dividends. Others look to bottom-line profits or rock-solid balance sheets. In other words, it’s subjective. 

Rather than spend excessive time settling on the best criteria for determining blue-chip stocks to buy for safety, I’ve selected seven names that appear in the holdings of one or more of the following blue-chip exchange-traded funds: Monarch Blue Chips Core ETF (BATS:MBCC), T. Rowe Price Blue Chip Growth ETF (NYSEARCA:TCHP) and Fidelity Blue Chip Growth ETF (BATS:FBCG).

As always, I’ll ensure that the selections provide reasonable sector diversification. In addition, the stock must have a positive annualized total return over the past one-year, three-year and five-year periods.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Here are seven blue-chip stocks to buy for safety and reduced volatility.

NEE

NextEra Energy 

$84.79

LLY

Eli Lilly

$308.89

AAPL

Apple

$150.70

TSLA

Tesla

$303.35

UNH

UnitedHealth Group

$521.02

SO

Southern Company

$77.25

COST

Costco Wholesale

$504.14

NextEra Energy (NEE)

Nextra Energy (NEE) website on a mobile phone screen
Nextra Energy (NEE) website on a mobile phone screen

Source: madamF / Shutterstock.com

NextEra Energy (NYSE:NEE) is not only one of my favorite utility stocks but also one of my favorite stocks, period. It’s a traditional power company through Florida Power & Light, the country’s largest electric utility with more than 5.7 million customer accounts. It’s also the world’s largest generator of renewable energy from wind and solar through its NextEra Energy Resources subsidiary. 

NEE has delivered an annualized total return of 2.9% over a one-year period, 17.8% over a three-year period and 19.5% over a five-year period, all significantly better than the S&P 500.

The company reported excellent second-quarter results in late July. Operating revenue of $5.18 billion was 32% higher than a year earlier. On the bottom line, operating income of $948 million was 86% higher than a year ago. 

Analysts expect earnings per share to increase 12.6% this year to $2.87 and 7.7% next year to $3.09. Based on its current share price, NEE stock trades at 29.5x 2022 earnings and 27.4x 2023 earnings. Add in a 2% dividend yield and I’m not sure how you couldn’t like NEE stock.

Eli Lilly (LLY)

Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals XI
Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals XI

Source: Jonathan Weiss / Shutterstock.com

Eli Lilly (NYSE:LLY) is an Indianapolis-based large-cap pharmaceutical company.  Ten years ago, its three top-selling drugs by revenue were Zyprexa (for treatment of schizophrenia), Cymbalta (for the treatment of depression and anxiety) and Alimta (for the treatment of lung carcinoma). Today, the company’s top three drugs’s are Trulicity (for diabetes), Taltz (for psoriasis) and Verzenio (for breast cancer).